Developed at Sheba Medical Center by Chief of Gastroenterology, Professor Shomron Ben-Horin, MD, and Director of Integrative Gastroenterology, Nir Salomon.
- No prescription needed
- No prior authorization needed
- Delivered straight to their doorstep
What is CurQD®?
CurQD® is a novel nutraceutical formulation developed by leading GI researchers and clinically tested at Sheba Medical Center, one of Newsweek’s top 10 hospitals in the world.
This unique formulation is a blend of gut-directed curcumin and a specifically sourced form of Indigo (Qing Dai, QD). CurQD® was developed into 6 different protocols used successfully in thousands cases in Israel and around the world, showing exceptional clinical efficacy and safety.
CurQD® was developed by Nir Salomon, a GI-trained herbalist who heads the Integrative Medicine Unit at Sheba, currently the largest IBD referral center in the country, and Prof. Shomron Ben-Horin M.D, a renowned IBD expert who has trained in Israel and the US, is a member of IOIBD, a previous SciCom member of ECCO, and an Editorial Board member of Gut, APT and JCC.
Evidence
A substantial and growing body of published academic work across several continents has explored CurQD®.
For example, an ultrasound-based evaluation conducted at the University of Chicago reported notable improvements in imaging-based gut parameters among individuals using CurQD®.
These and many other peer-reviewed studies examining tolerability, biological markers, imaging findings, and participant-reported experiences can be found on our Science Page.
Guidelines
Dosing & Personalization
• Protocols are individualized based on an online assessment provided through the assessment page.
• Adjustments over time follow observed responses and standardized ratio progressions.
Monitoring Recommendations
• A liver-enzyme blood test is recommended 4–6 weeks after beginning QD1.
• Mild, temporary elevations in transaminases (up to ~5× ULN) have been observed in a small proportion of users and may normalize with continued or adjusted dosing.
• Higher elevations are uncommon; if they occur, discontinuation of QD1 may be advised while Cura is often continued separately when appropriate.
Expected Early Reactions
• Mild headache may occur in 5–10% of individuals beginning QD1 and typically resolves with continued use, temporary dose reduction, or brief pause and restart.
Safety Notes
• Historical reports from Japan involving non-standard Qing Dai products have mentioned rare cases of pulmonary-related events. Such events have not been reported among individuals using CurQD®.
• As a precaution, QD1 is not recommended for individuals with a personal or family history of pulmonary arterial hypertension (PAH), deep-vein thrombosis (DVT), or serious cardiovascular, cerebrovascular, or liver conditions.
• Qing Dai has been rarely associated in literature with temporary episodes such as colonic narrowing or intussusception, typically resolving after discontinuation and conservative care.
Drug Interaction Considerations
• Curcumin is generally considered to have minimal interaction potential, but standard drug-interaction resources or our medical team may be consulted.
• No medication interactions have been documented to date with QD1.
Contraindications
• Not recommended during pregnancy.
In case of further questions please don’t hesitate to contact us at info@curqd.com.